NCI Outstanding Investigator Award (R35 Clinical Trial Optional)
ID: 342746Type: Posted
Overview

Buyer

National Institutes of Health (HHS-NIH11)

Award Range

$0 - $600K

Eligible Applicants

Others

Funding Category

Health

Funding Instrument

Grant

Opportunity Category

Discretionary

Cost Sharing or Matching Requirement

Yes

Original Source

https://grants.gov/search-results-detail/342746

Additional Information

http://grants.nih.gov/grants/guide/rfa-files/RFA-CA-22-045.html
Timeline
    Description

    The National Institutes of Health (NIH) is inviting applications for the NCI Outstanding Investigator Award (R35 Clinical Trial Optional), aimed at providing long-term support to accomplished cancer researchers. This grant opportunity encourages innovative, high-risk research that has the potential to lead to significant breakthroughs in biomedical, behavioral, or clinical cancer research, with funding available up to $600,000 in direct costs per year for a maximum of seven years. The program is particularly focused on supporting diverse institutions and underrepresented groups, requiring applicants to demonstrate a strong history of research contributions and commit at least six person-months to their proposed projects. Interested applicants should note that the application deadline is November 7, 2024, and can find further details and guidelines at the provided NIH link or contact the NIH OER Webmaster at OERWebmaster03@od.nih.gov for inquiries.

    Point(s) of Contact
    OERWebmaster03@od.nih.gov
    Files
    Title
    Posted
    RFA-CA-22-045-Full-Announcement.html
    RFA-CA-22-045.html
    The National Cancer Institute (NCI) is soliciting applications for the Outstanding Investigator Award (OIA), designed to provide long-term support to accomplished cancer researchers. This funding opportunity aims to encourage high-risk, innovative research that may lead to breakthroughs in biomedical, behavioral, or clinical cancer research. The OIA allows investigators to focus on projects that show exceptional potential, with funding up to $600,000 direct costs per year for a total of seven years. Eligibility extends to diverse institutions, including higher education institutions and nonprofits, with special encouragement for applications from underrepresented groups. Applicants must demonstrate a history of outstanding research contributions and commit at least 6 person-months to the project. The application process requires adherence to specific guidelines and includes peer review for scientific merit. NCI anticipates committing up to $17 million in FY 2023 for approximately 17 awards. Key administrative requirements include substantial institutional commitment, compliant application submissions, and a focus on inclusive research practices. This initiative underscores the government's commitment to advancing cancer research through innovative funding mechanisms.
    Similar Opportunities
    NCI Research Specialist (Clinician Scientist) Award (R50 Clinical Trial Not Allowed)
    Active
    National Institutes of Health
    The National Institutes of Health (NIH) is offering the NCI Research Specialist (Clinician Scientist) Award (R50), a federal grant aimed at supporting clinician scientists involved in NCI-funded clinical trials. This award is designed to provide salary support and autonomy for exceptional clinician scientists who will not serve as principal investigators but will lead in the development and implementation of national clinical trials and participate in scientific committees. The R50 Award is crucial for ensuring career stability in cancer research, allowing candidates to apply for new, renewal, or resubmission grants over a funding period of up to five years. Applications open on October 4, 2024, and interested parties can find more information and application details at the NIH grants website or contact NIH Grants Information at grantsinfo@nih.gov.
    NHLBI Outstanding Investigator Award (OIA) (R35 Clinical Trial Optional)
    Active
    National Institutes of Health
    The National Institutes of Health (NIH) is offering the NHLBI Outstanding Investigator Award (OIA), a federal grant aimed at supporting experienced Program Directors/Principal Investigators (PDs/PIs) engaged in heart, lung, blood, and sleep (HLBS) research. This award provides long-term funding of up to $700,000 annually for a maximum of seven years, allowing recipients to pursue innovative research initiatives without the constraints of predefined aims, thereby enhancing scientific productivity and flexibility. The OIA is designed to foster a stable research environment, reduce administrative burdens, and facilitate mentoring of junior scientists, with applications due by April 28, 2027. For further details, interested applicants can contact NIH Grants Information at grantsinfo@nih.gov or visit the opportunity's webpage at https://grants.nih.gov/grants/guide/rfa-files/RFA-HL-26-002.html.
    NCI Clinical and Translational Exploratory/Developmental Studies (R21 Clinical Trial Optional)
    Active
    National Institutes of Health
    The National Institutes of Health (NIH) is offering a funding opportunity through the R21 Clinical Trial Optional mechanism, aimed at supporting exploratory and developmental research in cancer diagnosis, treatment, imaging, symptom management, and prevention. This grant is designed to encourage innovative studies that challenge existing paradigms and address critical barriers in cancer research, particularly focusing on reducing disparities among underserved populations. Eligible applicants include a wide range of organizations, such as historically black colleges, tribal governments, and faith-based organizations, with a maximum funding amount of $275,000 available over a two-year period. Interested parties can find more information and application details at the provided link, with a submission deadline of July 1, 2025, and inquiries directed to the NIH OER Webmaster at OERWebmaster03@od.nih.gov.
    NCI Research Specialist (Core-based Scientist) Award (R50 Clinical Trial Not Allowed)
    Active
    National Institutes of Health
    The National Institutes of Health (NIH) is inviting applications for the NCI Research Specialist (Core-based Scientist) Award (R50), a federal grant aimed at supporting laboratory-based scientists involved in cancer research. This funding opportunity is designed to provide salary support and promote stable career paths for exceptional researchers who contribute significantly to NCI-funded projects but do not serve as independent investigators. The initiative emphasizes the importance of collaborative scientific support in advancing cancer research and aims to foster a sustainable research workforce, particularly among institutions serving underrepresented groups. Applications are open from October 2, 2023, with awards expected as early as November 2023, and interested parties can find more information and submit inquiries via grantsinfo@nih.gov. The project duration can extend up to five years, with funding covering the Research Specialist's salary and limited travel costs.
    NCI Pathway to Independence Award (K99/R00 Clinical Trial Not Allowed)
    Active
    National Institutes of Health
    The National Institutes of Health (NIH) is offering the NCI Pathway to Independence Award (K99/R00), a federal grant designed to support postdoctoral researchers transitioning to independent faculty positions in cancer research. This program provides funding for up to five years, consisting of a two-year mentored phase (K99) followed by up to three years of independent research support (R00), contingent upon securing a tenure-track position. The initiative aims to foster a diverse and skilled workforce in biomedical research, addressing critical health needs while promoting the career development of emerging investigators. Interested applicants must hold a clinical or research doctorate and have no more than six years of postdoctoral experience at the time of application. The application period opens on January 13, 2025, with a submission deadline of October 14, 2027. For further inquiries, applicants can contact NIH Grants Information at grantsinfo@nih.gov or visit the program's webpage at https://grants.nih.gov/grants/guide/pa-files/PAR-25-135.html.
    Maximizing Investigators' Research Award (R35 - Clinical Trial Optional)
    Active
    National Institutes of Health
    The National Institutes of Health (NIH) is offering the Maximizing Investigators' Research Award (R35 - Clinical Trial Optional) to support a broad program of research within the mission of the National Institute of General Medical Sciences (NIGMS). This grant aims to enhance the efficiency and efficacy of funding by providing stability and flexibility to investigators, allowing them to pursue diverse scientific inquiries over a five-year term, with funding levels capped at $750,000 in direct costs per year and typically set at $250,000 for New Investigators. The MIRA program is designed to reduce the application burden on researchers, encourage innovation, and foster diversity in the research workforce, with applications undergoing a rigorous peer review process. Interested applicants must submit their proposals by May 16, 2025, and can reach out to the NIH OER Webmaster at OERWebmaster03@od.nih.gov for further inquiries.
    NCI Clinical and Translational Exploratory/Developmental Studies (R21 Clinical Trial Optional)
    Active
    National Institutes of Health
    The National Institutes of Health (NIH), through the National Cancer Institute (NCI), is offering a funding opportunity titled "NCI Clinical and Translational Exploratory/Developmental Studies (R21 Clinical Trial Optional)" aimed at supporting innovative preclinical and early-phase clinical research in cancer diagnosis, treatment, and prevention. This grant, with a funding ceiling of $275,000 over two years, encourages exploratory studies that may involve significant risk but have the potential to lead to breakthroughs in cancer research, particularly for underserved populations. Applications will be evaluated based on their significance, innovation, and rigor, with key deadlines for submission set for January 2025. Interested applicants can find more information and contact NIH Grants Information at grantsinfo@nih.gov for inquiries.
    Exploratory Grant Award to Promote Workforce Diversity in Basic Cancer Research (R21 Clinical Trial Not Allowed)
    Active
    National Institutes of Health
    The National Institutes of Health (NIH), through the National Cancer Institute (NCI), has announced the "Exploratory Grant Award to Promote Workforce Diversity in Basic Cancer Research" (R21 Clinical Trial Not Allowed). This funding opportunity aims to enhance diversity among early-stage and junior investigators in cancer research, particularly from groups that are underrepresented in the biomedical, behavioral, clinical, and social sciences. The initiative encourages innovative studies in cancer biology, with a maximum funding amount of $275,000 available over a two-year period, and applications must demonstrate scientific merit and innovation. The application window opens on May 17, 2024, with the first awards expected to be made in June 2024; interested applicants can find more information and submission guidelines at the NIH grants website or contact NIH Grants Information at grantsinfo@nih.gov.
    NCI Small Grants Program for Cancer Research (NCI Omnibus) (R03 Clinical Trial Optional)
    Active
    National Institutes of Health
    The National Institutes of Health (NIH) has announced the NCI Small Grants Program for Cancer Research (R03), aimed at supporting short-term cancer research projects that require limited resources. This funding opportunity encourages diverse research efforts, including pilot studies, secondary data analyses, and the development of research methodologies, with a maximum budget of $50,000 per year for projects lasting up to two years. The program is designed to address significant knowledge gaps in cancer research and is open to a wide range of applicants, including public, private, and foreign entities. Interested parties should note that the application period opens on January 24, 2025, with a submission deadline of February 24, 2025. For further inquiries, applicants can contact NIH Grants Information at grantsinfo@nih.gov.
    The NCI Transition Career Development Award (K22 Independent Clinical Trial Optional)
    Active
    National Institutes of Health
    The National Institutes of Health (NIH) is offering the NCI Transition Career Development Award (K22), a federal grant aimed at supporting researchers transitioning from mentored, non-independent positions to their first independent tenure-track faculty roles in cancer research. This grant provides funding for up to three years, covering both salary and research development expenses, with the goal of enhancing the applicant's potential to secure independent NIH grants and fostering a diverse pool of capable scientists in the biomedical field. Eligible applicants include various institutions and organizations, particularly those serving underrepresented groups, and must adhere to detailed application guidelines. Interested parties can find more information and apply before the closing date of November 12, 2025, by visiting the NIH grants website or contacting NIH Grants Information at grantsinfo@nih.gov.